

Proposed Project Scope

Trametinib for recurrent low-grade serous ovarian cancer

Date: September 2024
For Stakeholder Input

Background and Rationale

CDA-AMC received a request from public drug programs for a Non-Sponsored Reimbursement Review of trametinib for recurrent low-grade serous ovarian cancer

Table I: Policy Questions

Item	Policy Question
1	Should trametinib be publicly reimbursed for patients with recurrent low-grade serous ovarian cancer?

Table II: Products Available in Canada

Product	Manufacturer
Trametinib	Novartis Pharmaceuticals Canada Inc.

Project Description

Table III: Project Scope

Criteria	Description
Population	Patients with recurrent low-grade serous ovarian cancer
Intervention(s)	Trametinib
Comparators	Standard-of-care treatments (paclitaxel, pegylated liposomal doxorubicin, topotecan, letrozole, or tamoxifen)
Outcomes	<p>Efficacy</p> <ul style="list-style-type: none"> Overall Survival Progression Free Survival <p>Safety</p> <ul style="list-style-type: none"> Adverse events Serious adverse events Withdrawal due to adverse events Mortality Notable harms

Table IV: Research Questions

Item	Policy Question
1	What is the effectiveness of trametinib for recurrent low-grade serous ovarian cancer?
2	What are the harms associated with trametinib for recurrent low-grade serous ovarian cancer?
3	What is the expected cost of trametinib for recurrent low-grade serous ovarian cancer vs. other reimbursed regimes?

Key Project and Protocol Components

This project will follow the [Procedures for Non-Sponsored Reimbursement Reviews](#).

Status of the Document

This proposed project scope is being posted for information.